Skip to main content

Advertisement

Log in

Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves’ disease

  • Case Report
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Interferon (IFN)-β has become a widespread therapy for multiple sclerosis. As already reported for IFN-α, thyroid autoimmunity and dysfunctions have been observed also in course of IFN-β therapy. Nevertheless, very few cases of Graves’ disease, occurred in such condition, have been reported in literature. We here describe the case of a 40-year-old female affected by multiple sclerosis, who received IFN-β-1b, 8 million IU sc every other day for her condition. After 22 months of cytokine administration, she developed a severe Graves’ disease with persistently positive TRAb which suggested the withdrawal of the treatment. Our patient had performed a complete thyroid evaluation with normal findings, before and during the first 6 months of therapy. This case suggests that patients undergoing long-term IFN-β therapy should be monitored for thyroid hormones and antibodies throughout the treatment as thyroidal side effect can be a late event.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. The IFN β Multiple Sclerosis Study Group. Interferon beta 1-b is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43: 655–661.

    Article  Google Scholar 

  2. The IFN β Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta 1-b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995, 45: 1277–1285.

    Article  Google Scholar 

  3. Burman P., Karlsson F.A., Oberg K., Alm G. Autoimmune thyroid disease in interferon treated patients. Lancet 1985, 8946: 100–101.

    Article  Google Scholar 

  4. Carella C., Amato G., Biondi B., Rotondi M., Morisco F., Tuccillo C., Chiuchiolo N., Signoriello G., Caporaso N., Lombardi G. Longitudinal study of antibodies against thyroid in patients undergoing interferon-a therapy for HCV chronic hepatitis. Horm. Res. 1995, 44: 110–114.

    Article  CAS  PubMed  Google Scholar 

  5. Roti E., Minelli R., Giuberti T., Marchelli S., Schianchi C., Gardini E., Salvi M., Fiaccadori F., Ugolotti G., Neri T.M., Braverman L.E. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am. J. Med. 1996, 172: 482–487.

    Article  Google Scholar 

  6. Marazuela M., García-Buey L., González-Fernández B., García-Monzón C., Arranz A., Borque M.J., Moreno-Otero R. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-a therapy. Clin. Endocrinol. 1996, 44: 635–642.

    Article  CAS  Google Scholar 

  7. Pagliacci M.C., Pelicci G., Schippa M., Liberati A.M., Nicoletti I. Does Interferon-β therapy induce thyroid autoimmune phenomena? Horm. Metab. Res. 1991, 23: 196–197.

    Article  CAS  PubMed  Google Scholar 

  8. Nagai Y., Ohsawa K., Ieki Y., Kobayashi K. Effect of interferon-beta on thyroid function in patients of chronic hepatitis C without preexisting autoimmune thyroid disease. Endocr. J. 1996, 43: 545–549.

    Article  CAS  PubMed  Google Scholar 

  9. Schwid S.R., Goodman A.D., Mattson D.H. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch. Neurol. 1997, 54: 1169–1170.

    Article  CAS  PubMed  Google Scholar 

  10. Martinelli V., Gironi M., Rodegher M., Martino G., Comi G. Occurence of thyroid autoimmunity in relapsing-remitting multiple sclerosis patients undergoing interferon-β treatment. It. J. Neur. Sci. 1998, 19: 65–67.

    Article  CAS  Google Scholar 

  11. Rotondi M., Oliviero A., Profice P., Mone C.M., Biondi B., Del Buono A., Mazziotti G., Sinisi A.M., Bellastella A., Carella C. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-β therapy for multiple sclerosis. J. Endocrinol. Invest. 1998, 21: 748–752.

    CAS  PubMed  Google Scholar 

  12. Durelli L., Ferrero B., Oggero A., Verdun E., Bongioanni M.R., Gentile E., Isoardo G.L., Ricci A., Rota E., Bergamasco B., Durazzo M., Saracco G., Biava M.A., Brossa P.C., Giorda L., Pagni R., Aimo G. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J. Neurol. Sci. 1999, 162: 74–83.

    Article  CAS  PubMed  Google Scholar 

  13. Monzani F., Caraccio N., Meucci G., Lombardo F., Moscato G., Casolaro A., Ferdeghini M., Murri L., Ferrannini E. Effect of 1-year treatment with interferon-β1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur. J. Endocrinol. 1999, 141: 325–331.

    Article  CAS  PubMed  Google Scholar 

  14. Poser C.M., Paty D.W., Scheinberg L., Mc Donald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.A., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13: 227–231.

    Article  CAS  PubMed  Google Scholar 

  15. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33: 1444–1452.

    Article  CAS  PubMed  Google Scholar 

  16. Kivisakk P., Lundahl J., Von Heigl Z., Fredrikson S. No evidence for increased frequency of autoantibodies during interferon-β1b treatment of multiple sclerosis. Acta Neurol. Scand. 1998, 97: 320–323.

    Article  CAS  PubMed  Google Scholar 

  17. De Keiser J. Autoimmunity in multiple sclerosis. Neurology 1988, 38: 371–374.

    Article  Google Scholar 

  18. Kiessling W.R., Pflughaupt K.W. Antithyroid antibodies in multiple sclerosis. Lancet 1980, 1: 41.

    Article  CAS  PubMed  Google Scholar 

  19. Conlon K., Urba W., Smith J., Steis R., Longo D., Clark J. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990, 65: 2237–2242.

    Article  CAS  PubMed  Google Scholar 

  20. Vial T., Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995, 105: 31–57.

    Article  CAS  PubMed  Google Scholar 

  21. Baudin E., Marcellin P., Pouteau M., Colas-Linhart N., Le Floch J.P., Lemmonier C., Benhamou J.P., Bok B. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin. Endocrinol. 1993, 39: 657–661.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rotondi, M., Mazziotti, G., Biondi, B. et al. Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves’ disease. J Endocrinol Invest 23, 321–324 (2000). https://doi.org/10.1007/BF03343730

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343730

Key-words

Navigation